Results for: Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (ALNY) has submitted an application to the European Medicines Agency seeking approval for vutrisiran to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). The application is fueled by positive results from the HELIOS-B phase III study, showcasing vutrisiran’s potential to improve patient outcomes and become a standard of care for ATTR-CM. This expansion signifies Alnylam’s continued commitment to innovating in the treatment of rare diseases and could drive significant growth for the company.

Alnylam Pharmaceuticals’ stock declined after the company revealed mixed results from the HELIOS-B trial for its investigational RNAi treatment, Amvuttra. While the study met its primary endpoint of reducing mortality and cardiovascular events, the reduction in mortality was not statistically significant, potentially impacting investor sentiment. Despite the setback, Amvuttra remains a key revenue driver for Alnylam and is expected to become a standard treatment for ATTR amyloidosis with cardiomyopathy.